🇺🇸 S-1 in United States
126 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 126
Most-reported reactions
- Diarrhoea — 16 reports (12.7%)
- Decreased Appetite — 15 reports (11.9%)
- Fatigue — 15 reports (11.9%)
- Neutropenia — 15 reports (11.9%)
- Nausea — 13 reports (10.32%)
- Anaemia — 12 reports (9.52%)
- Leukopenia — 11 reports (8.73%)
- Stomatitis — 10 reports (7.94%)
- Thrombocytopenia — 10 reports (7.94%)
- Pyrexia — 9 reports (7.14%)
Other Oncology approved in United States
Frequently asked questions
Is S-1 approved in United States?
S-1 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for S-1 in United States?
TTY Biopharm is the originator. The local marketing authorisation holder may differ — check the official source linked above.